Synonym
Clobetasol; HSDB7994; HSDB-7994; HSDB 7994
IUPAC/Chemical Name
Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11beta,16beta)-
InChi Key
FCSHDIVRCWTZOX-DVTGEIKXSA-N
InChi Code
InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
SMILES Code
C[C@@]12[C@](C(CCl)=O)(O)[C@@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
410.91
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wright WC, Chenge J, Wang J, Girvan HM, Yang L, Chai SC, Huber AD, Wu J, Oladimeji PO, Munro AW, Chen T. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. J Med Chem. 2020 Feb 13;63(3):1415-1433. doi: 10.1021/acs.jmedchem.9b02067. Epub 2020 Jan 22. PMID: 31965799; PMCID: PMC7087482.
2: Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol. 2001;2(2):89-92; discussion 93. doi: 10.2165/00128071-200102020-00005. PMID: 11705308.
3: Pels R, Sterry W, Lademann J. Clobetasol propionate--where, when, why? Drugs Today (Barc). 2008 Jul;44(7):547-57. doi: 10.1358/dot.2008.44.7.1122221. PMID: 18806904.
4: Bhutani T, Koo J, Maibach HI. Efficacy of clobetasol spray: factors beyond patient compliance. J Dermatolog Treat. 2012 Feb;23(1):11-5. doi: 10.3109/09546634.2010.512952. Epub 2011 Jan 22. PMID: 21254848.
5: Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009;10(6):397-406. doi: 10.2165/11311020-000000000-00000. PMID: 19824740.
6: Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol. 2006 Jun;5(6):527-32. PMID: 16774104.
7: Reid DC, Kimball AB. Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother. 2005 Aug;6(10):1735-40. doi: 10.1517/14656566.6.10.1735. PMID: 16086659.
8: Olsen EA, Cornell RC. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol. 1986 Aug;15(2 Pt 1):246-55. doi: 10.1016/s0190-9622(86)70164-3. PMID: 3528243.
9: Zeiai S, Wåhlin N, Fossum M. Klobetasol i första hand vid fimos hos barn [Clobetasol primarily used for phimosis in children]. Lakartidningen. 2015 Apr 14;112:DE3W. Swedish. PMID: 25872191.
10: Menter A. Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis. Cutis. 2012 Feb;89(2):89-94. PMID: 22474733.
